Efficiency and safety of phenazopyridine for treatment of uncomplicated urinary tract infection: results of multi-center, randomized, placebo-controlled, clinical  study

Петров, С. Б.; Slesarevskaya, M N; Chibirov, K H; Topuzov, Marlen; Kagan, O F; Воронова, Е. Н.

doi:10.18565/urology.2020.3.15-21

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most well studied intervention is phenazopyridine, a urinary tract analgesic indicated for short-term treatment of irritation in the lower urinary tract. Phenazopyridine has proven effective in relieving dysuria and pain in acute uncomplicated urinary tract infections (Petrov et al, 2020 ), IC/BPS (Lusty et al, 2018 ), and perioperatively for urological procedures (Stewart et al, 2022 ). High quality data on the use of phenazopyridine for BCG-cystitis induced LUTS is lacking, however, clinical guidelines and cancer survivors indicate it is commonly prescribed (Kassouf et al, 2015 ; Babjuk et al, 2022 ).…”

Section: Clinical Management Strategies For Bcg Induced Lutsmentioning

confidence: 99%

BCG induced lower urinary tract symptoms during treatment for NMIBC—Mechanisms and management strategies

Bourlotos,

Baigent,

Hong

et al. 2024

Front. Neurosci.

View full text Add to dashboard Cite

Non-muscle invasive bladder cancer (NMIBC) accounts for ~70–75% of total bladder cancer tumors and requires effective early intervention to avert progression. The cornerstone of high-risk NMIBC treatment involves trans-urethral resection of the tumor followed by intravesical Bacillus Calmette-Guerin (BCG) immunotherapy. However, BCG therapy is commonly accompanied by significant lower urinary tract symptoms (LUTS) including urinary urgency, urinary frequency, dysuria, and pelvic pain which can undermine treatment adherence and clinical outcomes. Despite this burden, the mechanisms underlying the development of BCG-induced LUTS have yet to be characterized. This review provides a unique perspective on the mechanisms thought to be responsible for the development of BCG-induced LUTS by focussing on the sensory nerves responsible for bladder sensory transduction. This review focuses on how the physiological response to BCG, including inflammation, urothelial permeability, and direct interactions between BCG and sensory nerves could drive bladder afferent sensitization leading to the development of LUTS. Additionally, this review provides an up-to-date summary of the latest clinical data exploring interventions to relieve BCG-induced LUTS, including therapeutic targeting of bladder contractions, inflammation, increased bladder permeability, and direct inhibition of bladder sensory signaling. Addressing the clinical burden of BCG-induced LUTS holds significant potential to enhance patient quality of life, treatment compliance, and overall outcomes in NMIBC management. However, the lack of knowledge on the pathophysiological mechanisms that drive BCG-induced LUTS has limited the development of novel and efficacious therapeutic options. Further research is urgently required to unravel the mechanisms that drive BCG-induced LUTS.

show abstract

Section: Clinical Management Strategies For Bcg Induced Lutsmentioning

confidence: 99%

BCG induced lower urinary tract symptoms during treatment for NMIBC—Mechanisms and management strategies

Bourlotos,

Baigent,

Hong

et al. 2024

Front. Neurosci.

View full text Add to dashboard Cite

show abstract

A Randomized Controlled Trial Comparing a New D-Mannose-based Dietary Supplement to Placebo for the Treatment of Uncomplicated Escherichia coli Urinary Tract Infections

Salvatore¹,

Ruffolo²,

Stabile³

et al. 2023

European Urology Focus

View full text Add to dashboard Cite

Modern Combined Treatment of Acute Complicated Cystitis in Women

Davidov,

Meltsina,

Bunova

et al. 2023

Vrach

View full text Add to dashboard Cite

One of the most common human diseases is acute cystitis, which affects mainly women. Annually in Russia there are 26-36 million cases of acute cystitis. The most severe contingent is considered to be patients with acute complicated cystitis, whose treatment efficiency is only 64.6–85.8% or less. Objective. Evaluation of the analgesic effect, efficacy and tolerability of phenazopyridine in combination with the antibiotic cefixime for the treatment of acute complicated cystitis in women of working age. Material and methods. A multicenter randomized open study of phenazopyridine in combination with the antibiotic cefixime in the treatment of 144 women with an average age of 42.2±3.8 years with acute complicated cystitis was performed in 5 polyclinics of the Perm region. In 55.6% of patients, the risk factors were not urological, but therapeutic and gynecological diseases. The international scale of cystitis ACSS, visual analogue scale (VAS) of pain, laboratory and bacteriological methods were used. The main group consisted of 72 women who received oral phenazopyridine (Urinalgin F) at a dose of 200 mg 3 times a day for 2 days and cefixime 400 mg 1 time per day for 7 days. The comparison group consisted of 72 women who received orally cefixime at the same dose for 7 days and No-spa (drotaverine hydrochloride) 80 mg 3 times a day for 2 days. Results. In the main group, a strong analgesic and antidysuric effect of phenazopyridine was noticed, which was confirmed by the analysis of the ACSS and VAS scales. Already after 20 minutes, an analgesic effect was detected, after 2 days pain symptoms and dysuria completely disappeared in 70 (97.2%) patients, despite the high initial level. The pain index on the VAS scale decreased from the initial 6.5 points to 0.03 points, i.e. by 217 times. The clinical efficacy (recovery) of combination therapy with phenazopyridine and cefixime was 91.7%, bacteriological efficacy was 91.8%, leukocyturia disappeared earlier, and the period of temporary disability decreased by 28.6%. In the comparison group, clinical (83.3%) and bacteriological (83.6%) efficiency was lower. Urinalgin F showed a favorable safety profile, only 1 (1.4%) patient had a side effect (nausea). Conclusion. Phenazopyridine (Urinalgin F) is a drug with high effectiveness and tolerability that eliminates pain, dysuria and other symptoms of acute complicated cystitis, eliminates leukocyturia earlier and more significantly, and reduces the period of temporary disability by 28.6%. Combined therapy of acute complicated cystitis with the antibiotic cefixime and the selective analgesic Urinalgin F has a high clinical and bacteriological efficacy.

show abstract

Efficiency and safety of phenazopyridine for treatment of uncomplicated urinary tract infection: results of multi-center, randomized, placebo-controlled, clinical study

Cited by 3 publications

References 0 publications

BCG induced lower urinary tract symptoms during treatment for NMIBC—Mechanisms and management strategies

BCG induced lower urinary tract symptoms during treatment for NMIBC—Mechanisms and management strategies

A Randomized Controlled Trial Comparing a New D-Mannose-based Dietary Supplement to Placebo for the Treatment of Uncomplicated Escherichia coli Urinary Tract Infections

Modern Combined Treatment of Acute Complicated Cystitis in Women

Contact Info

Product

Resources

About